CANCER

On the following pages you will find information on both mainstream and advanced Cancer treatments. Utopia Research Institute’s aim within these pages is the advancement of medical education, research, and health care.

Conflict of Interest [Between Health Care and the pharmaceutical industry]

Cancer treatment and healthcare in general are driven by the pharmaceutical industry. The insurance industry also plays a major part in cancer care; however, for the purposes of this book, the insurance industry will not be discussed. When it comes to the pharmaceutical industry, writing prescriptions plays a large role in the life of a physician. In the rare case that a physician doesn’t write a prescription during an office visit, the patient is usually disappointed.

Physicians are groomed in the practice of giving out drugs even before they’ve completed medical school and started their internships and residencies. Young medical students are conditioned early in their training by pharmaceutical reps who visit them, usually about once a week while still in school to persuade them to prescribe particular brands of drugs. This relationship continues during residency training and throughout their careers. Often given incentives or gifts by the reps, in the form of free samples, meals, entertainment, research and continuing education funding, trips, and other personal services, this behavior has come under the scrutiny of medical ethicists and often by the medical students themselves.

One  study that investigated the attitude of medical students and physicians toward the pharmaceutical reps who visit them found that “most believe that representatives prioritize product promotion above patients’ welfare and are likely to use unethical  practices.” This relationship between doctors and drug companies has generated a financial conflict of interest. Although most physicians deny any bias when it comes to receiving gifts and writing prescriptions, “A positive correlation has been found between the cost of physicians’ treatment choices and their amount of contact with the pharmaceutical company representatives.” REF

Burzynski Research Institute (BRI) is based in Houston and Stafford, Texas, U.S.A., and is engaged in research and development of targeted gene therapies (antineoplastons or ANP) for the treatment of cancer and engages in the research, production, marketing, promotion and sale of medical chemical compounds composed of growth-inhibitig peptides, amino acid derivatives and organic acids which are known under the trade name antineoplastons. See: Antineoplaston Cancer Therapy – Dr Burzynski